Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00157274|
Recruitment Status : Unknown
Verified September 2005 by Latin American Cooperative Onco-Haematology Group - Peru.
Recruitment status was: Recruiting
First Posted : September 12, 2005
Last Update Posted : April 3, 2007
|Condition or disease||Intervention/treatment||Phase|
|Mycosis Fungoides Sezary Syndrome||Drug: alemtuzumab||Phase 2|
- 20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days during the first week, followed by 30 mg three times a week until 12 weeks.
- Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until three different regimens of chemotherapy.
- Follow up for one year after last cycle of alemtuzumab.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome|
|Study Start Date :||July 2005|
|Estimated Study Completion Date :||July 2008|
- Overall response
- Time to relapse
- Event free survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00157274
|Contact: Julia M Huamani, MDemail@example.com|
|Schering Peruana S.A.||Recruiting|
|Lima, Peru, 511|
|Contact: Jesus A Arones, MD 99480078 firstname.lastname@example.org|
|Principal Investigator:||Brady E Beltran, MD||LACOGH - PERU|